Risk Factors for Disseminated Tuberculosis and Associated Survival in Adults Without Human Immunodeficiency Virus

被引:0
作者
Huang, Wei [1 ]
Fei, Zhentao [1 ]
Yan, Bo [2 ]
Liu, Xuhui [1 ]
Liu, Ping [1 ]
Xia, Lu [1 ]
Liu, Huarui [1 ]
Xi, Xiuhong [1 ]
Ye, Dan [1 ]
Shen, Yinzhong [3 ]
机构
[1] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept TB, Shanghai, Peoples R China
[2] Fudan Univ, Ctr TB Res, Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect & Immun, Shanghai, Peoples R China
来源
OPEN FORUM INFECTIOUS DISEASES | 2025年 / 12卷 / 01期
关键词
tuberculosis; adult; disseminated tuberculosis; risk factor; survival analysis; STAGE RENAL-DISEASE; MORTALITY;
D O I
10.1093/ofid/ofae739
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background The global resurgence of disseminated tuberculosis (TB) after the coronavirus disease 2019 pandemic highlights the necessity of understanding host risk factors, especially in adults without human immunodeficiency virus. Methods We reviewed TB cases admitted to Shanghai Public Health Clinical Center from 2017 to 2022. We analyzed baseline characteristics and outcomes. To identify risk factors for disseminated TB, as well as its subsite distribution and mortality, we employed logistic regression and Cox proportional hazards models. Results Among 1062 patients, including 283 with disseminated TB, 558 with pulmonary TB (PTB), and 221 with extrapulmonary TB, those with disseminated TB had the highest mortality rate. The following factors were associated with disseminated TB: age >= 45 years, body mass index (BMI) <18.5 kg/m(2), immunosuppressive therapy, and end-stage renal disease (ESRD). A BMI <18.5 kg/m(2) was found to correlate with all subsites of disseminated TB, while aged >= 45 years specifically increased incidence of bone and joint TB. Female patients showed a higher risk for lymphatic, peritoneal, and intestinal TB. Additionally, immunosuppressive therapy and ESRD were linked to various TB subsites. During a 12-month follow-up period, 19.8% of patients with disseminated TB died. Factors contributing to reduced survival included BMI <18.5 kg/m(2), immunosuppressive therapy, ESRD, pulmonary cavities, and meningeal involvement. Conclusions Age, low BMI, immunosuppressive therapy, and ESRD are significant risk factors for disseminated TB and also significantly impact patient survival rates. These findings are of great importance for the development of clinical management and preventive measures.
引用
收藏
页数:11
相关论文
共 37 条
  • [1] Treatment outcome of new smear positive pulmonary tuberculosis patients in Penang, Malaysia
    Atif, Muhammad
    Sulaiman, Syed Azhar Syed
    Shafie, Asrul Akmal
    Ali, Irfhan
    Asif, Muhammad
    Babar, Zaheer-Ud-Din
    [J]. BMC INFECTIOUS DISEASES, 2014, 14
  • [2] Increase in disseminated TB during the COVID-19 pandemic
    Barrett, J.
    Painter, H.
    Rajgopal, A.
    Keane, D.
    John, L.
    Papineni, P.
    Whittington, A.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2021, 25 (02) : 160 - 161
  • [3] Cardiovascular morbidity and mortality among persons diagnosed with tuberculosis: A systematic review and meta-analysis
    Basham, Christopher Andrew
    Smith, Sarah J.
    Romanowski, Kamila
    Johnston, James C.
    [J]. PLOS ONE, 2020, 15 (07):
  • [4] Association of BMI Category Change with TB Treatment Mortality in HIV-Positive Smear-Negative and Extrapulmonary TB Patients in Myanmar and Zimbabwe
    Benova, Lenka
    Fielding, Katherine
    Greig, Jane
    Nyang'wa, Bern-Thomas
    Casas, Esther Carrillo
    da Fonseca, Marcio Silveira
    du Cros, Philipp
    [J]. PLOS ONE, 2012, 7 (04):
  • [5] Nutritional support for adult patients with microbiologically confirmed pulmonary tuberculosis: outcomes in a programmatic cohort nested within the RATIONS trial in Jharkhand, India
    Bhargava, Anurag
    Bhargava, Madhavi
    Meher, Ajay
    Teja, G. Sai
    Velayutham, Banurekha
    Watson, Basilea
    Benedetti, Andrea
    Barik, Ganesh
    Singh, Vivek Pratap
    Singh, Dhananjay
    Madhukeshwar, Adarsh Kibballi
    Prasad, Ranjit
    Pathak, Rajeev Ranjan
    Chadha, Vineet
    Joshi, Rajendra
    [J]. LANCET GLOBAL HEALTH, 2023, 11 (09): : E1402 - E1411
  • [6] Prednisolone dose during treatment of tuberculosis might be a risk factor for mortality in patients with systemic lupus erythematosus: a hospital-based cohort study
    Cheng, C. F.
    Huang, Y. M.
    Lu, C. H.
    Hsieh, S. C.
    Li, K. J.
    [J]. LUPUS, 2019, 28 (14) : 1699 - 1704
  • [7] Immune Dysfunction in Uremia 2020
    Cohen, Gerald
    [J]. TOXINS, 2020, 12 (07)
  • [8] Two decades of disseminated tuberculosis at a University Medical Center: The expanding role of mycobacterial blood culture
    Crump, JA
    Reller, LB
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (08) : 1037 - 1043
  • [9] Diagnostic standards and classification of tuberculosis in adults and children
    Dunlap, NE
    Bass, J
    Fujiwara, P
    Hopewell, P
    Horsburgh, CR
    Salfinger, M
    Simone, PM
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (04) : 1376 - 1395
  • [10] Gaiter Z, 2017, INT J MYCOBACT, V6, P162, DOI 10.4103/ijmy.ijmy_31_17